Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305-5407, USA.
Future Cardiol. 2021 Jan;17(1):11-17. doi: 10.2217/fca-2020-0070. Epub 2020 Jul 6.
Orthotopic heart transplantation is the gold standard treatment for end-stage heart failure. However, the persistent shortage of available donor organs has resulted in an ever-increasing waitlist and longer waiting periods for transplantation. On the contrary, increasing the number of heart transplants by preserving extended criteria donors and donation after circulatory death hearts with the Organ Care System™ (OCS) Heart System has the potential to provide the gold standard, life-saving treatment to patients with end-stage heart failure. The objective of the Donation After Circulatory Death Heart Trial is to evaluate the effectiveness of the OCS Heart System to preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation, which can potentially provide patients with end-stage heart failure with the life-saving treatment. Clinical Trial Registration: NCT03831048 (ClinicalTrials.gov).
原位心脏移植是治疗终末期心力衰竭的金标准。然而，由于可供使用的捐献器官持续短缺，导致候补名单不断增加，移植等待时间也越来越长。相反，通过保存扩展标准供体和使用器官保存系统（OCS）心脏系统进行循环死亡后捐献的心脏来增加心脏移植数量，有可能为终末期心力衰竭患者提供标准的、救命的治疗。循环死亡后心脏捐献试验的目的是评估 OCS 心脏系统保存和评估循环死亡后捐献的心脏用于移植的效果，以增加可用于移植的供体心脏数量，从而有可能为终末期心力衰竭患者提供救命的治疗。临床试验注册：NCT03831048（ClinicalTrials.gov）。
